Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) subsidiary Teva Pharmaceuticals USA Inc. spent $620,000 on lobbying Congress and federal agencies, according to its Lobbying Report for the third quarter, filed under the Lobbying Disclosures Act of 1995. Teva USA spent 6% less on lobbying than in the corresponding quarter of 2011.
Teva USA spent $2.3 million on lobbying in January-September, targeting both houses of Congress, the US Patent and Trademark Office, the US Trade Representative, and other federal agencies.
Teva cited the following lobbying issues in which the company has an interest: funding for FDA offices, the Preserving Access to Life-Saving Medications Act, women's issues relating to healthcare reform law, implementation of biologics provisions of healthcare reform law, prescription drug abuse/diversion proposals, the Affordable Medicines Utilization Act of 2011, the Fair & Immediate Release of Generic Drugs Act, the Generic Drug Application Review Fairness Act, the FDA Innovation & Safety Act, the Patient Safety & Generic Labeling Improvement Act, the Drug Safety and Accountability Act, the Consumer Protection Recall Act of 2011, Medicaid pharmacy issues, and the Trans-Pacific Partnership Trade Agreement.
Published by Globes [online], Israel business news - www.globes-online.com - on October 23, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012